BiotechTube

EG-70 (phase 1) + EG-70 (phase 2)

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Superficial Bladder Cancer

Conditions

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Trial Timeline

Apr 22, 2021 → Nov 30, 2028

NCT ID
NCT04752722

About EG-70 (phase 1) + EG-70 (phase 2)

EG-70 (phase 1) + EG-70 (phase 2) is a phase 1/2 stage product being developed by enGene for Superficial Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04752722. Target conditions include Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ.

What happened to similar drugs?

2 of 5 similar drugs in Superficial Bladder Cancer were approved

Approved (2) Terminated (1) Active (2)
✅Diclofenac gelNovartisApproved
✅Dalteparin sodium injectionPfizerApproved
🔄Rivaroxaban + FondaparinuxBayerPhase 3
🔄Rivaroxaban + PlaceboBayerPhase 3
❌NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04752722Phase 1/2Recruiting

Competing Products

11 competing products in Superficial Bladder Cancer

See all competitors
ProductCompanyStageHype Score
GemcitabineEli LillyPhase 2
35
Gemcitabine + mitomycin CEli LillyPhase 2
35
MK-3475 and BCGMerckPhase 2
42
Diclofenac gelNovartisApproved
43
LDE225 0.75% + VehicleNovartisPhase 2
27
Dalteparin sodium injectionPfizerApproved
43
Rivaroxaban + FondaparinuxBayerPhase 3
37
Rivaroxaban + PlaceboBayerPhase 3
37
ChemophaseHalozyme TherapeuticsPhase 1
26
NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3
26
EscharEx 5% (EX-02 formulation)MediWoundPhase 1/2
29